Early safety check for experimental drugs begins
NCT ID NCT07260851
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing the safety and how the body handles three experimental drugs—DWJ1622, DWC202313, and DWC202314—in 40 healthy adults. Participants take a single dose of each drug under fasting conditions. The study aims to measure drug levels in the blood and check for any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DWJ1622, DWC202313, DWC202314 (oral drugs)
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, so it only tests safety and drug processing—not whether the drugs work for any disease. The results may not apply to patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H Plus YANGJI Hospital
RECRUITINGSeoul, Gwanak-gu, 08779, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults